Drug Profile
Daclatasvir\sofosbuvir - Mylan Laboratories
Alternative Names: Sofosbuvir\daclatasvirLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Mylan Laboratories Limited
- Class Antivirals; Biphenyl compounds; Carbamates; Imidazoles; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-C in India (PO, Tablet)
- 26 Sep 2020 University of Witwatersrand plans a phase II trial in COVID-2019 infections (Combination therapy) in South Africa (PO) in December 2020 (NCT04561063)
- 05 Dec 2017 Chemical structure information added